← All indications
Keratosis, Actinic
White or pink lesions on the arms, hands, face, or scalp that arise from sun-induced DNA DAMAGE to KERATINOCYTES in exposed areas. They are considered precursor lesions to superficial SQUAMOUS CELL CARCINOMA.
Drugs by status
Approved for this indication (9)
Phase 4 trials (8)
Phase 3 trials (10)
Phase 2 trials (34)
- melatonin
- vda-1102
- vitamin d3
- act01
- ad17137
- afamelanotide
- ak 3012
- ethanol
- paclitaxel
- idea-070
- iloperidone
- imipramine
- lfx453
- T4-bacteriophage endonuclease V
- oleogel-s10
- resiquimod
- solamargine
- cholesterol
- digoxin
- furosemide
- human papillomavirus 9-valent vaccine, recombinant
- lovastatin
- clindamycin
- lactic acid
- resorcinol
- hexyl 5-aminolevulinate
- isotretinoin
- tretinoin
- benzoyl peroxide
- bimiralisib
- +4 more
Phase 1 trials (6)
Other trials (6)
Organizations
Organization Involved with Phase 4 Indications (49)
- Galderma
- AboutSkin Dermatology and DermSurgery, PC
- Meda
- Aclaris Therapeutics, Inc.
- Medicis
- Sanofi
- Graceway
- Derm Research @ 888 Inc.
- German Research Foundation
- Frankel, Amylynne, M.D.
- Goldman, Butterwick, Fitzpatrick and Groff
- Maastricht University
- Ajou University
- Dong-A University
- Korea University
- Kunming Medical University
- Rigel Dermatology
- Seoul National University
- University of Dundee
- University of Regensburg
- University of Tampere
- Wake Forest University
- University of Valencia
- Yonsei University
- Dermatology, Laser & Vein Specialists of the Carolinas
- Fudan University
- Peking University
- Tennessee Clinical Research Center
- University of California, Irvine
- University of California, San Francisco
- +19 more
Organization Involved with Phase 3 Indications (47)
- Peplin
- Actavis
- Perrigo
- Apotex
- Almirall
- Applied Genetic Technologies Corp
- Biofrontera Bioscience GmbH
- Encube Ethicals Pvt. Ltd.
- G&E Herbal Biotechnology Co., LTD
- Spear Pharmaceuticals
- Therapeutics, Inc.
- Teva
- Capstone Therapeutics
- Sol-Gel Technologies, Ltd.
- National Cancer Institute (NCI)
- Barretos Cancer Hospital
- National Cheng Kung University
- Radboud University
- Texas Tech University
- Universidad Complutense de Madrid
- University of Rochester
- University of Bonn
- University of Zurich
- University of British Columbia
- University of Chicago
- Vancouver Coastal Health
- University of Limoges
- Laser & Skin Surgery Center of Indiana
- Long Island Skin Center
- Altman Dermatology Associates
- +17 more
Organization Involved with Phase 2 Indications (43)
- DFB Pharma
- Bausch Health Companies
- Novartis
- AmDerma
- Birken AG
- Clinuvel Pharmaceuticals Limited
- Cutanea Life Sciences, Inc.
- Dolorgiet GmbH & Co. KG
- IDEA AG
- Moberg Pharma AB
- Spirig Pharma Ltd.
- Sponsor GmbH
- Vidac Pharma
- Case Western Reserve University
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Harvard University
- Northwestern University
- Universidade do Vale do Sapucai
- University of Sydney
- Pacific Dermaesthetics
- Leiden University
- Bangladesh Medical University
- US Biotest
- Long Island Skin Cancer and Dermatologic Surgery
- The Education & Research Foundation, Inc.
- Oregon Medical Research Center
- Specialist Connect
- Theorem Clinical Research
- Chao Family Comprehensive Cancer Center
- Gwinnett Clinical Research Center, Inc
- +13 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (9)